MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)

NCT07892651 | Not Yet Recruiting

• 2 other identifiers: AXM-CHR-001AXM Fund
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including individuals with chronic medical conditions and healthy volunteers. The registry will collect standardized clinical and participant-reported data, along with biological samples, to support the investigation of disease patterns, health-related characteristics, and population-specific biological and immunological profiles in populations historically underrepresented in biomedical research. The resulting data and samples may support future research into disease-associated biomarkers and underlying biological mechanisms.

Conditions

Antiphospholipid (aPL)-Positive; Rheumatic Arthritis; Celiac Disease; Focal Segmental Glomerulosclerosis (FSGS); Membranous Nephropathy; Crohn Disease (CD); Type 1 Diabetes Mellitus; Alport Syndrome; Pompe Disease; Alzheimer s Disease; Urea Cycle Disorder; System Lupus Erythematosus; Hyperlipidemia; Inherited Thrombophilia; Sickle Cell Disease (SCD); Parkinson Disease (PD)

Outcome Measures

Primary Outcomes (1)

• Distribution of Enrolled Participants by Clinical Condition

  Number and percentage of enrolled participants with each eligible chronic medical condition, including disease subtype where applicable. Healthy volunteers will be summarized separately from participants with chronic medical conditions.

  At the enrollment/sample collection visit

Other Outcomes (2)

• Demographic and Anthropometric Characteristics of the Enrolled Population

  At the enrollment/sample collection visit

• Geographic Distribution of the Enrolled Population

  At the enrollment/sample collection visit

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Individuals of Middle Eastern, North African, or Levantine ancestry, including both participants with chronic conditions and healthy volunteers.

You may qualify if:

• Individuals of Middle Eastern, North African, or Levantine ancestry, as determined by participant self-report.
• Individuals aged 18 years or older with chronic medical conditions; a confirmed diagnosis or self-reported history of one or more chronic medical conditions, supported by medical record review where available.
• Individuals below 18 years of age with a relevant chronic condition, where pediatric enrollment is subject to applicable ethical approvals and the required parental or legally authorized representative permission and participant assent, as applicable.
• Healthy volunteers: Individuals aged 18 years or older without known chronic medical conditions relevant to the registry, based on participant self-report and investigator assessment.
• Willing and able to provide written informed consent before initiation of any study procedures or, for pediatric participants, participation will be subject to applicable written parental/legal guardian permission and assent procedures, as appropriate.
• Eligible and willing to undergo the applicable study procedures, including collection of relevant clinical information and biological samples.

You may not qualify if:

• Inability to obtain the required informed consent, parental or legally authorized representative permission, or participant assent, as applicable.
• Acute illness, including fever (≥38°C), active infection, or a clinically unstable condition at the time of enrollment that, in the opinion of the investigator, may compromise participant safety or interfere with study procedures. Enrollment may be deferred until the condition resolves or the participant is clinically stable.

Sponsors & Collaborators

• Axiom Bioregistry: lead

Study Sites (1)

Biosenses

Amman, Jordan

Location

MeSH Terms

Conditions

Rheumatic Fever; Celiac Disease; Glomerulosclerosis, Focal Segmental; Glomerulonephritis, Membranous; Crohn Disease; Diabetes Mellitus, Type 1; Nephritis, Hereditary; Glycogen Storage Disease Type II; Urea Cycle Disorders, Inborn; Lupus Erythematosus, Systemic; Hyperlipidemias; Anemia, Sickle Cell; Parkinson Disease

Condition Hierarchy (Ancestors)

Streptococcal Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases; Inflammatory Bowel Diseases; Gastroenteritis; Diabetes Mellitus; Glucose Metabolism Disorders; Endocrine System Diseases; Urogenital Abnormalities; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Collagen Diseases; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Glycogen Storage Disease; Carbohydrate Metabolism, Inborn Errors; Lysosomal Storage Diseases; Amino Acid Metabolism, Inborn Errors; Dyslipidemias; Lipid Metabolism Disorders; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemoglobinopathies; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Design

• Study Type: observational
• Observational Model: ECOLOGIC OR COMMUNITY
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 10, 2026
• First Posted: October 23, 2026
• Study Start: October 18, 2026
• Primary Completion (Estimated): October 1, 2028
• Study Completion (Estimated): October 1, 2029
• Last Updated: October 23, 2026

Record last verified: 2026-10

Locations

JO (1)